CPI-637 is primarily investigated for its potential in epigenetic cancer therapy. It functions as a selective inhibitor of the bromodomain and extra-terminal (BET) family proteins, which play a key role in the regulation of gene expression linked to tumor growth and cell proliferation. By targeting BET proteins, CPI-637 disrupts the transcription of oncogenes such as MYC, making it a promising candidate for the treatment of certain hematologic malignancies and solid tumors. Its application is especially relevant in cancers where dysregulation of epigenetic signaling contributes to disease progression. Preclinical studies suggest CPI-637 may offer improved selectivity and reduced toxicity compared to earlier BET inhibitors, supporting ongoing evaluation in targeted cancer therapies.